Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Equivalents (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Cash & Equivalents data on record, last reported at $466.2 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 13.35% year-over-year to $466.2 million; the TTM value through Dec 2025 reached $466.2 million, up 13.35%, while the annual FY2025 figure was $466.2 million, 13.35% up from the prior year.
  • Cash & Equivalents reached $466.2 million in Q4 2025 per APLS's latest filing, down from $479.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $765.1 million in Q1 2023 and bottomed at $265.4 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $459.4 million, with a median of $431.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 138.65% in 2022, then plummeted 57.4% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $640.2 million in 2021, then fell by 13.81% to $551.8 million in 2022, then crashed by 36.36% to $351.2 million in 2023, then increased by 17.11% to $411.3 million in 2024, then grew by 13.35% to $466.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $466.2 million in Q4 2025, $479.2 million in Q3 2025, and $370.0 million in Q2 2025.